Sarepta Therapeutics Says FDA Will Not Complete Eteplirsen Review By PDUFA Date; Stock Surges
May 25, 2016 at 08:09 AM EDT
Sarepta Therapeutics Inc (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, revealed Wednesday that the U.S. Food and ...